| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/14/2009 | US7517669 Increasing the intracellular amount of at least one ferritin-H or a derivative to an effective level for suppressing disease caused or enhanced by effects of intracellular iron mismanagement |
| 04/14/2009 | US7517667 Methods for promoting, inhibiting and detecting toxin entry into cells |
| 04/14/2009 | US7517661 Methods of screening for ligands for FPRL2 |
| 04/14/2009 | US7517659 Comprises nucleotide sequences coding tandem of P domains in a weak inward rectifying potassium channel (TWIK) for identifying modulators and treatment of pain and headache disorders |
| 04/14/2009 | US7517658 Drug screening for human SNORF33 receptor agonist by contacting cells transfected with and expressing DNA encoding the human SNORF33 receptor, wherein cells prior to being transfected with the DNA do not express the human SNORF33 receptor; inflammation, infections, arthritis; autoimmune diseases |
| 04/14/2009 | US7517654 polypeptides used as wound healing agents, tissue regeneration, inhibition of cancer metastesis mediated by extracellular matrix protein including laminin |
| 04/14/2009 | US7517649 Contacting a sample with a nucleic acid molecule encoding OGFr and determining the level of the mRNA encoding said OGFr; antisense molecules, expression vectors and host cells, and proteins; anticarcinogenic and wound healing agents; drug screening |
| 04/14/2009 | US7517533 Pseudomonas aeruginosa antigens |
| 04/14/2009 | US7517531 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
| 04/14/2009 | US7517530 Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency comprising administration of IGF-1 and growth hormone |
| 04/14/2009 | US7517529 Using gene-regulatory peptide |
| 04/14/2009 | US7517528 Method and composition for treating skin wounds with epidermal growth factor |
| 04/14/2009 | US7517526 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 04/14/2009 | US7517525 Methods of inhibiting amyloid toxicity |
| 04/14/2009 | US7517522 Disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS); ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases; von Willebrand bactor cleaving protease activity; treating acquired thrombotic thrombocytopenic purpura; anticoagulant drug development |
| 04/14/2009 | US7517519 Topical immune disorders of the scalp, and scalp conditions; immunosuppressant selected from the group consisting of tacrolimus, cyclosporin and carrier therefor, as a mousse, foamable on dispensing |
| 04/14/2009 | CA2474988C Polymeric matrices and their uses in pharmaceutical compositions |
| 04/14/2009 | CA2318576C Antibodies, including fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| 04/14/2009 | CA2307175C Modified vitamin k-dependent polypeptides |
| 04/14/2009 | CA2240256C Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
| 04/14/2009 | CA2234231C Stabilizing formulation for ngf |
| 04/14/2009 | CA2232378C Aerosol compositions |
| 04/14/2009 | CA2230819C Medicament comprising hgf gene |
| 04/14/2009 | CA2227891C Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations |
| 04/14/2009 | CA2225852C Anti-fas ligand antibody and assay method using the anti-fas ligand antibody |
| 04/14/2009 | CA2219460C Lhrh antagonist peptides |
| 04/14/2009 | CA2213261C Therapeutics of osteoarthritis and inflammatory joint disease |
| 04/14/2009 | CA2208237C Nuclear protein serine/threonine kinases |
| 04/14/2009 | CA2204493C Application of superoxide dismutase in liposomes |
| 04/14/2009 | CA2166204C Pharmaceutical compositions for sparingly soluble therapeutic agents |
| 04/14/2009 | CA2130900C Therapeutic domains of von willebrand factor |
| 04/14/2009 | CA2106249C Solutions for the perfusion, preservation and reperfusion of organs |
| 04/09/2009 | WO2009046464A1 Articular cartilage gene therapy with recombinant vector encoding bmp-7 |
| 04/09/2009 | WO2009046453A2 Use of neuregulin-1 in reducing brain damage |
| 04/09/2009 | WO2009046436A1 Methods for inhibiting senescence of epithelial cells |
| 04/09/2009 | WO2009046377A2 Compositions and methods of stem cell therapy for autism |
| 04/09/2009 | WO2009046369A2 Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| 04/09/2009 | WO2009046322A2 Compositions and methods for treating neural anoxia and spreading depression |
| 04/09/2009 | WO2009046314A2 Moenomycin analogs, methods of synthesis, and uses thereof |
| 04/09/2009 | WO2009046129A2 Methods for treating adult respiratory distress syndrome |
| 04/09/2009 | WO2009046015A2 Combination therapies for treating type 1 diabetes |
| 04/09/2009 | WO2009045894A1 Methods and structural conformations of antibody preparations with increased resistance to proteases |
| 04/09/2009 | WO2009045837A1 Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
| 04/09/2009 | WO2009045800A1 Treatment of cardiovascular disorders using the cell differentiation signaling protein nell1 |
| 04/09/2009 | WO2009045596A2 Optimized dengue virus entry inhibitory peptide (10an) |
| 04/09/2009 | WO2009045508A1 Novel protein transduction domains derived from secretory leukocyte protease inhibitor |
| 04/09/2009 | WO2009045412A2 Methods of treatment using modified plasminogen activator inhibitor type-1 molecules |
| 04/09/2009 | WO2009045397A1 Methods for treating polycystic kidney desease (pkd) or other cyst forming diseases |
| 04/09/2009 | WO2009045309A2 Use of v2 receptor antagonists in combination with vasopressinergic agonists |
| 04/09/2009 | WO2009045179A1 Taz/wwtr1 for diagnosis and treatment of cancer |
| 04/09/2009 | WO2009045123A1 Medicinal agent exhibiting hemopoiesis-stimulating and hepatoprotective actions |
| 04/09/2009 | WO2009045122A1 Medicinal agent for treating and preventing diabetes complications |
| 04/09/2009 | WO2009044918A1 Neuromedin u derivative |
| 04/09/2009 | WO2009044787A1 Remedy for tendon rupture disease comprising tenomodulin as the active ingredient |
| 04/09/2009 | WO2009044722A1 Gene susceptible to disease associated with intervertebral disc degeneration and use thereof |
| 04/09/2009 | WO2009044406A2 Stearically stabilized unilamilar vesicles, process for preparation thereof and use thereof |
| 04/09/2009 | WO2009044383A1 Nucleic acid codifying for a utrophin transcription specific regulating protein, protein codified thereby and uses thereof |
| 04/09/2009 | WO2009044279A2 Peptides having antimicrobial and/or biosurfactant properties |
| 04/09/2009 | WO2009044273A2 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| 04/09/2009 | WO2009044173A2 Methods of treating cancer using notch pathway inhibitors |
| 04/09/2009 | WO2009044059A2 Implantable preparations containing globin, method for the production thereof and uses |
| 04/09/2009 | WO2009043963A1 Use of the sequence encoding the carboxyl-terminal domain of the heavy chain of tetanus toxin as a drug |
| 04/09/2009 | WO2009043940A2 Peptides with high affinity for the prolactin receptor |
| 04/09/2009 | WO2009043874A1 Dispersion of poloxamer- protein particles, methods of manufacturing and uses thereof |
| 04/09/2009 | WO2009043529A1 Thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043528A1 Substance p and thyrotropin releasing hormone for therapeutic applications |
| 04/09/2009 | WO2009043527A2 Therapeutic use of human growth hormone 1-43 |
| 04/09/2009 | WO2009043525A2 Use of the combination of gluten exorphin c and cd36 as a therapeutic agent |
| 04/09/2009 | WO2009043524A2 Use of a peptide as therapeutic agent |
| 04/09/2009 | WO2009043523A2 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 04/09/2009 | WO2009043522A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043521A2 Use of urocortin iii and urocortin i as therapeutic agents |
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043518A2 Use of a combination of cart peptides as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043476A2 Neuromedin s as a therapeutic agent |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043468A2 Use of corticotropin-releasing factor as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043464A2 Astressin and beta- endorphin for use as therapeutic agents |
| 04/09/2009 | WO2009043463A2 Use of gluten exorphin c : as a therapeutic agent |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043453A2 Use of a peptide as a therapeutic agent |